Welcome to

Our Event


Over the past several years, many immuno-oncology modalities have emerged. These modalities, which include checkpoint inhibition, adoptive T-cell therapy (ACT), and cancer vaccines, are often designed to evade immune responses. This is a rapidly growing therapeutic field that embraces the concept of modulating the immune system to recognize tumor cells and target them for destruction. Our Next Gen Immuno-Oncology Congress from past 2 years had gathered the professionals across the globe to deliver such latest developments.


Awesome Image

2 DAY EVENT

50 SPEAKERS

250 TICKETS

10 Hours of Networking

Agenda

Time Speaker Name Presentation Title
09:00 Eugene Zhukovsky Opening remarks from the Chairman
09:00 Stefan Glueck Opening remarks from the Chairman
09:05 Michelle Morrow Keynote: Bispecific Antibodies to Deliver the Next Immuno-Oncology Breakthrough
09:05 Kandeepan Ganeshaligam Checkpoint inhibitors as a therapeutic strategy in Oncology
09:35 Stephen Beers Optimising anti-cancer therapy with immune stimulatory antibodies: When opposites co-act
09:35 Robert Hawkins The future of Tumour Infiltrating Lymphocyte(TIL) based therapies
10:05 Emiliano Melandri Validation methods and innovative tools in IO Discovery
10:05 David Giljohann Innate immune activators- spherical nucleic acid tlr9 in combination with checkpoint inhibitors
11:25 Will Arends Immuno-oncology and the Patent Maze
11:25 Mark Creighton-Gutteridge GSK’s Oncology Cell Therapy
11:55 Thomas Valerius Improving recruitment of myeloid effector cells for antibody therapy
11:55 Angela Vasaturo From Staining to Analysis: End-to-End Application of UltiMapper™
12:25 Lucia Pattarini Bispecific antibody-based therapeutics to modulate T cell activation
12:25 Dimitris Lagos Cancer-associated non-coding RNAs in immunity: A new space for immunotherapeutics?
13:55 Sophia Karagiannis Monoclonal antibody approaches for triple-negative breast cancer
13:55 John Maudsley Vaccines: the Next Generation I-O: addressing the needs
13:55 Zoe Johnson PI3Kd: A new era in immuno-oncology
14:35 Heinz Lubenau Oral T-Cell Therapies for the Treatment of Cancer Patients
14:35 Louise Affleck HTRF Assays + Reagents for Immuno-Oncology Drug Discovery
14:35 Christian Gojak Human Cell Culture Models for Cancer Immunotherapy Development
15:05 Mike Dyson Immune checkpoint inhibitor antibody discovery
15:05 Angus Dalgleish On the Requirement to Induce Immune Modulation Prior to Check Point Inhibitor Therapy
15:05 Deborah Wright AgenTus Therapeutics: Developing Novel TCRs for Cancer Therapy
15:35 Sebastien Tabruyn Humanized Mouse Models for Immuno-Oncology Research
15:35 Liselotte Brix dCODE Dextramer® technology, unravelling T cell immunity at the single cell level
15:35 Jeanette Leusen IgA recruits neutrophils for tumorkill, combination with innate checkpoint inhibition
16:55 Juliette Lamy In Vitro Functional Bioassays for Evaluating Candidate Therapeutic Effectiveness in Immuno-Oncology
16:55 Thomas Mørch Frøsig The ImmuMap take on immune monitoring
16:55 Esther Breij Discovery of novel bispecific antibody molecules to boost anti-tumor immunity
17:25 Awesome Image Closing remarks from the Chairman
Time Speaker Name Presentation Title
09:00 Ann White Opening remarks from the Chairman
09:00 Stefan Glueck Opening remarks from the Chairman
09:05 Stefan Glueck Keynote: Why are we so late in treatment of breast cancer using ICI?
09:05 Awesome Image Andrew Sewell Keynote: What can we learn by dissecting immunotherapy successes?
09:35 Carolyn Edwards CB307: A novel CD137/4-1BB agonist Humabody Therapeutic
09:35 Renier Heijkants MAGE-A/MHC-I as target for immunotherapy: challenges and opportunities
10:05 Eugene Zhukovsky BiXAb® - a Plug-and-Play tetra-Fab antibody platform
10:05 Robin Campbell Neoscreen Case Study and perspective
11:25 Kathrin Thell Ambulatory Adoptive Cell Immunotherapy of Master Checkpoint
11:25 Lolke de Haan Challenges in the Development of mAb-based Immune Agonists
11:55 Christoph Wuelfing PD-1 suppresses the maintenance of cell couples between cytotoxic T cells
11:55 Robert Boyd Accelerating Immune oncology therapeutic development
12:25 Anneli Anderson Validation markers for tumor derived T-cell sub-populations
12:25 John Bridgeman Gene-Engineering strategies for Tumour Infiltrating Lymphocytes
13:55 Katja Klausz Targeting the tumor-associated glyco-antigen CD75s
13:55 Lindy Durrant Stress induced post translational modifications
14:25 Ann White Breakout Session : Strategies for targeting costimulatory receptors for cancer therapy
14:25 Alex Blyth Using cancer killing neutrophils to destroy all solid tumours
14:55 Awesome Image Closing remarks from the Chairman
Full Name *
Email Id *

Company *
Job Title *

Country Code *
Phone Number *

Country *




Advisors

Eugene	Zhukovsky
Eugene Zhukovsky

CSO

Biomunex Pharmaceuticals

Jeanette	Leusen
Jeanette Leusen

Group Leader, Tumor Immunology

UMC Utrecht

Sophia Karagiannis
Sophia Karagiannis

Head of Cancer Antibody Discovery and Immunotherapy

King's College London

Stefan Glueck
Stefan Glueck

Vice President, Global Medical Affairs Solid Tumors, Immuno-Oncology and Early Assets, Clegene

Celgene

USA



Our Speakers

Eugene	Zhukovsky
Eugene Zhukovsky

CSO

Biomunex Pharmaceuticals

Jeanette	Leusen
Jeanette Leusen

Group Leader, Tumor Immunology

UMC Utrecht

Lindy Durrant
Lindy Durrant

Professor, CSO

Nottingham University, Scancell Ltd

Sophia Karagiannis
Sophia Karagiannis

Head of Cancer Antibody Discovery and Immunotherapy

King's College London

Thomas Valerius
Thomas Valerius

Professor-Department of stem cell and immunotherapy

Kiel Life Science, Germany

Stefan Glueck
Stefan Glueck

Vice President, Global Medical Affairs Solid Tumors, Immuno-Oncology and Early Assets, Clegene

Celgene

Kandeepan Ganeshaligam
Kandeepan Ganeshaligam

Executive Director, Oncology Therapeutic Area Head

Merck Sharp & Dohme Ltd, UK

Robert Hawkins
Robert Hawkins

Professor & Medical Oncologist, University of Manchester


Know All Speakers


Event Sponsors

Platinium

Diamond

Gold

Silver

Sponsors & Exhibitors

Official Logistics Partner


Become Sponsor Know All Sponsors


Media Partners


Supporting Association



Submit your Poster Presentation

Venue

ILEC Conference Centre and IBIS London Earls Court

 3rd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress  will be held at 

ILEC Conference Centre and IBIS London Earls Court,

 47 Lillie Road, London, SW6 1UD
 
 

Hotel Booking Link

Accommodation is currently available at the ILEC Conference Centre and IBIS London Earls Court at a discounted rate. You will receive a link to book your accommodation via once you are fully registered. (Please note that we do not authorize any 3rd party agencies (e.g. Exhibitors Housing Management) to book on our behalf and, occasionally, companies fraudulently try to represent us. If you are contacted by anyone other than us regarding your accommodation requirements for this event, please let us know immediately on events@marketsandmarkets.com

 

About the Hotel

ILEC Conference Centre is best known for the formidable flexibility and large capacity of its conference hall. It’s a West London Conference venue and is only a short ride away from London greatest landmarks, the venue is an ideal location for UK and overseas visitors. The conference hall offers a formidable flexibility to adapt to any event. Choose among many possible configurations, split, divide and create a conference space that fits your needs.

For further information, please contact: Email: events@marketsandmarkets.com


View on Map
Image Gallery
Loading...